Slingshot Insights | Xlrn Overview

XLRN Overview

Upcoming Projects (XLRN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (XLRN)

Quarterly Survey: LR-MDS RBC Transfusions and treatments including Luspatercept and Epoetin Alfa October 2024
Tickers: GERN, ELRN, MRK, XLRN, BMY
Executed On: Oct 29, 2024 at 01:33 PM EDT
Quarterly Survey: LR-MDS RBC Transfusions and treatments including Luspatercept and Epoetin Alfa July 2024
Tickers: GERN, ELRN, MRK, XLRN, BMY
Executed On: Jul 26, 2024 at 12:36 PM EDT
Quarterly Survey: LR-MDS RBC Transfusions and treatments including Luspatercept and Epoetin Alfa April 2024
Tickers: BMY, GERN, ELRN, MRK, XLRN
Executed On: Apr 24, 2024 at 04:44 PM EDT
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) January 2024
Tickers: BMY, GERN, ELRN, MRK, XLRN
Executed On: Jan 24, 2024 at 10:49 AM EST
Quarterly Survey: BMY's Reblozyl (luspatercept) and LR-MDS requiring Red Blood Cell Transfusions May 2023
Tickers: BMY, XLRN, MRK, GERN
Executed On: May 10, 2023 at 12:29 PM EDT

Upcoming & Overdue Catalysts (XLRN)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (XLRN)

Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept are expected in mid-2018
Ticker: XLRN
Occurred on: Jun 28, 2018
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
Tickers: CELG, XLRN
Occurred on: Jun 10, 2016

Strategic Initiatives (XLRN)

Don’t see a strategic initiative related to the company you care about? Create your own!